20201105 Transgene Q3 business upradta EN
Category: 2020
Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
20201105 TG – Neoantigen summit presentation
Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201027 – TG4001+avelumab abstract data SITC – EN
Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201019 TG4001+avelumab SITC – EN
Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201015 – BT-001_SITC poster EN
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
20201006 Transgene_NEC_BostonGene_Press_Release_final
High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al. Molecular Therapy Oncolytics, September 2020 – Read the article and view videos Publication
Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022
20200916 Results H1 2020 EN
Transgene Announces Upcoming Investor Meetings
20200909 Next investor events
Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
20200908 Transgene TG6002 Phase 1 EN
